Literature DB >> 28736343

TFOS DEWS II Management and Therapy Report.

Lyndon Jones1, Laura E Downie2, Donald Korb3, Jose M Benitez-Del-Castillo4, Reza Dana5, Sophie X Deng6, Pham N Dong7, Gerd Geerling8, Richard Yudi Hida9, Yang Liu10, Kyoung Yul Seo11, Joseph Tauber12, Tais H Wakamatsu13, Jianjiang Xu14, James S Wolffsohn15, Jennifer P Craig16.   

Abstract

The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dry eye disease; Dry eye workshop; Management; TFOS DEWS II; Therapy

Mesh:

Year:  2017        PMID: 28736343     DOI: 10.1016/j.jtos.2017.05.006

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  204 in total

1.  Manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin, a superoxide dismutase mimetic, reduces disease severity in in vitro and in vivo models for dry-eye disease.

Authors:  Agnė Žiniauskaitė; Symantas Ragauskas; Anita K Ghosh; Rubina Thapa; Anne E Roessler; Peter Koulen; Giedrius Kalesnykas; Jenni J Hakkarainen; Simon Kaja
Journal:  Ocul Surf       Date:  2019-02-23       Impact factor: 5.033

2.  Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics.

Authors:  Penny A Asbell; Maureen G Maguire; Ellen Peskin; Vatinee Y Bunya; Eric J Kuklinski
Journal:  Contemp Clin Trials       Date:  2018-06-06       Impact factor: 2.226

Review 3.  TFOS DEWS II Tear Film Report.

Authors:  Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

4.  Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease.

Authors:  Jennifer Hind; Elisabeth Macdonald; David Lockington
Journal:  Eye (Lond)       Date:  2018-11-29       Impact factor: 3.775

Review 5.  [Novel current and future therapy options for treatment of dry eye disease].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2018-02       Impact factor: 1.059

6.  Ocular Complications in School-Age Children and Adolescents after Allogeneic Bone Marrow Transplantation.

Authors:  Mary Ellen Hoehn; Robert Vestal; Julie Calderwood; Edwin Gannon; Brittany Cook; Richard Rochester; Christine Hartford; Brandon Triplett; Anusha Sunkara; Guolian Kang; R Christopher Walton
Journal:  Am J Ophthalmol       Date:  2020-03-12       Impact factor: 5.258

Review 7.  A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Authors:  Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

8.  Efficacy and retention of silicone punctal plugs for treatment of dry eye in patients with and without ocular graft-versus-host-disease.

Authors:  Rohan Bir Singh; Ann Yung; Giulia Coco; Shruti Sinha; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2020-07-30       Impact factor: 5.033

Review 9.  Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

10.  Reliability of Chinese web-based ocular surface disease index questionnaire in dry eye patients: a randomized, crossover study.

Authors:  Xin-Mei Zhang; Lan-Ting Yang; Qing Zhang; Qing-Xia Fan; Can Zhang; Yue You; Chen-Guang Zhang; Tie-Zhu Lin; Ling Xu; Salissou Moutari; Jonathan E Moore; Emmanuel E Pazo; Wei He
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.